The drug, called MK3475, is part of a clinical trial at the South Texas Accelerated Research Therapeutics Center, known around the world as the START center.
Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus
We aimed to assess the association between pre-treatment neutrophil-to-lymphocyte ratio (NLR) and the outcome of patients treated with everolimus for mRCC.
Tyrosine kinase inhibitors with activity against vascular endothelial growth factor receptor 2 are now standard treatment for the majority of patients with advanced renal cell carcinoma.
Immunohistochemistry for PAX8 and GATA3 are sensitive markers for renal cell carcinoma and urothelial carcinoma, respectively.
Organization is Ranked in Top 3% of US Charities for Six Consecutive Years
Puts charity in top 3% in USA. This is the sixth consecutive year the Kidney Cancer Association (KCA) has earned this top distinction.
Hollywood celebrity Denise Richards who is originally from the Chicago area, is a member of KCA's governing board. Her mother died from kidney cancer in 2007, and Denise is helping the charity to raise funds and awareness. KCA's board meets over the symposium weekend, and Richards has been invited to attend both meetings.
Sponsored by the Kidney Cancer Association (KCA) in cooperation with the Society for Immunotherapy in Cancer (SITC), this annual meeting brings together key individuals and representatives from leading laboratories and centers working with renal cell carcinoma.
Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood cancer drug with multibillion-dollar sales potential.
The company, which intends to use the funds for its Phase 3 clinical study of AGS-003, also plans to have data from its Phase 2b study of AGS-004 for the treatment of HIV in the first half of 2014.
|NeonCRM by Neon One|